Hossam Samir El-Sawy

Dr. Hossam Samir El-Sawy

Pharmaceutics and Pharmaceutical Technology, Egyptian Russian University, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Khalid M El-SayKhalid M El-Say
Khalid M El-Say
HEHossam Samir El-Sawy
Hossam Samir El-Sawy

17 October 2018 in ACS Nano
Verified
Journal Article
Closed access
HEHossam Samir El-Sawy
Hossam Samir El-Sawy
AAAhmed Al-Abd
Ahmed Al-Abd
AAAhmed Al-Abd
Ahmed Al-Abd
Khalid M El-SayKhalid M El-Say
Khalid M El-Say
VTVladimir P. Torchilin
Vladimir P. Torchilin

1 January 2017 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MKMohammed A. Kassem
Mohammed A. Kassem
HEHossam Samir El-Sawy
Hossam Samir El-Sawy
FAFathy I. Abd-Allah
Fathy I. Abd-Allah
TATamer M. Abdelghany
Tamer M. Abdelghany
Khalid M El-SayKhalid M El-Say
Khalid M El-Say

18 February 2018 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
MSMahmoud S. Soliman
Mahmoud S. Soliman
FAFathy I. Abd-Allah
Fathy I. Abd-Allah
THTalib Hussain
Talib Hussain
NSNoha M. Saeed
Noha M. Saeed
HEHossam Samir El-Sawy
Hossam Samir El-Sawy
Objective: An optimized date seed oil (DSO) loaded niosomes was formulated. Significance: Maximize the extract anti-inflammatory efficacy and govern its release characteristics from nanoparticles for osteoarthritis prevention and treatment purposes. Methods: By using Box–Behnken Design, the effect of three formulation factors on the entrapment efficiency percentage (Y1), initial DSO release percentage after 2 h (Y2), and cumulative DSO release percentage of DSO after 12 h (Y3), were optimized and studied. The optimized DSO formulation was specified, elaborated, particle size and zeta potential assessed, examined morphologically under electron and light microscope, and in vivo evaluated via carrageenan-induced rat paw edema study. Results: 65.89%, 18.39%, and 58.27% were the measured responses of the optimized niosomes for Y1, Y2, and Y3, respectively. The vesicular structure of the optimized DSO loaded nano-vesicles with nano-size range and good stability features were confirmed. Furthermore, a distinguished anti-inflammatory activity in both prompt and sustained effectiveness were exhibited via the optimized DSO niosomes. Interestingly, the delayed efficacy outcomes of the extract loaded nanoparticles showed a similarity profile as well as the negative control group outcomes. Conclusions: To emphasize, DSO loading in niosomes revealed a significant enhancement toward inflammation alleviation, which offers a promising implement in osteoarthritis remediation and prohibition.

17 February 2021 in Journal of Microencapsulation
Verified
Journal Article
Closed access
MDMohamed H. Desoqi
Mohamed H. Desoqi
HEHossam Samir El-Sawy
Hossam Samir El-Sawy
EKElsayed Kafagy
Elsayed Kafagy
MGMamdouh Ghorab
Mamdouh Ghorab
Shadeed GadShadeed Gad
Shadeed Gad
This work aimed to elaborate an optimised fluticasone propionate (FP)–loaded solid lipid nanoparticles (SLNs) to enhance FP effectiveness for topical inflammatory remediation. The influences of drug amount, lipid, and surfactant ratios, on drug release pattern and stability were investigated utilising Box-Behnken design. Elaboration, characterisation, and pharmacodynamic evaluation in comparison with the marketed formulation (Cutivate® cream, 0.05%w/w FP), were conducted for the optimised SLNs. The optimised SLNs with a size of 248.3 ± 1.89 nm (PDI = 0.275) and −32.4 ± 2.85 mV zeta potential were evidenced good stability physiognomies. The optimised SLNs pre-treated rats exhibited non-significant difference in paw volume from that of the control group and showed a significant reduction in both PGE2 and TNF-α levels by 51.5 and 61%, respectively, in comparison with the Carrageenan group. The optimised FP–loaded SLNs maximised the efficacy of FP towards inflammation alleviation that increase its potential as efficient implement in inflammatory skin diseases remediation.

14 March 2023 in Drug Delivery
Verified
Journal Article
Open access
SASaeed A. S. Al-Zuhairy
Saeed A. S. Al-Zuhairy
MTMahmoud Teaima
Mahmoud Teaima
NSNabil A. Shoman
Nabil A. Shoman
MEMohamed Elasaly
Mohamed Elasaly
MEMohamed A. El-Nabarawi
Mohamed A. El-Nabarawi
HEHossam Samir El-Sawy
Hossam Samir El-Sawy
A PEGylated Tween 80–functionalized chitosan–lipidic (PEG-T-Chito-Lip) nano-vesicular hybrid was developed for intranasal administration as an alternative delivery route to help improve the poor oral bioavailability of BCS class-III model/antiemetic (metoclopramide hydrochloride; MTC). The influence of varying levels of chitosan, cholesterol, PEG 600, and Tween 80 on the stability/release parameters of the formulated nanovesicles was optimized using Draper-Lin Design. Two optimized formulations (Opti-Max and Opti-Min) with both maximized and minimized MTC-release goals, were predicted, characterized, and proved their vesicular outline via light/electron microscopy, along with the mutual prompt/extended in-vitro release patterns. The dual-optimized MTC–loaded PEG-T-Chito-Lip nanovesicles were loaded in intranasal in-situ gel (ISG) and further underwent in-vivo pharmacokinetics/nose-to-brain delivery valuation on Sprague-Dawley rats. The absorption profiles in plasma (plasma-AUC0-∞) of the intranasal dual-optimized MTC–loaded nano-vesicular ISG formulation in pretreated rats were 2.95-fold and 1.64-fold more than rats pretreated with orally administered MTC and intranasally administered raw MTC-loaded ISG formulation, respectively. Interestingly, the brain-AUC0-∞ of the intranasal dual-optimized MTC–loaded ISG was 10 and 3 times more than brain-AUC0-∞ of the MTC-oral tablet and the intranasal raw MTC-loaded ISG, respectively. It was also revealed that the intranasal dual-optimized ISG significantly had the lowest liver-AUC0-∞ (862.19 ng.g−1.h−1) versus the MTC-oral tablet (5732.17 ng.g−1.h−1) and the intranasal raw MTC-loaded ISG (1799.69 ng.g−1.h−1). The brain/blood ratio profile for the intranasal dual-optimized ISG was significantly enhanced over all other MTC formulations (P < 0.05). Moreover, the 198.55% drug targeting efficiency, 75.26% nose-to-brain direct transport percentage, and 4.06 drug targeting index of the dual-optimized formulation were significantly higher than those of the raw MTC-loaded ISG formulation. The performance of the dual-optimized PEG-T-Chito-Lip nano-vesicular hybrids for intranasal administration evidenced MTC-improved bioavailability, circumvented hepatic metabolism, and enhanced brain targetability, with increased potentiality in heightening the convenience and compliance for patients.